StockData
LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25

LIFECORE BIOMEDICAL, INC. DE

Financials through Q4 FY2025, quarter ended May 25, 2025Last filing: 10-Q on Aug 5, 2026
$6.39+0.01 (+0.16%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

About Lifecore Biomedical, Inc. De

Pharmaceutical Preparations, SIC 2834

Lifecore Biomedical, Inc. is a contract development and manufacturing organization that specializes in the development, manufacturing, and aseptic filling of sterile injectable pharmaceutical drugs and medical devices. The company manufactures pharmaceutical-grade hyaluronic acid through bacterial fermentation in both bulk and filled formats such as syringes, vials, and cartridges, alongside non-hyaluronic acid formulations. Its service offerings include formulation development, analytical method validation, process scale-up, stability testing, and clinical trial material production. Lifecore manages its operations through a single integrated business segment. The company serves emerging and global biopharmaceutical and biotechnology firms, as well as academic and commercial research organizations.

The company is headquartered in Chaska, Minnesota, where it operates three manufacturing facilities encompassing a total of 250,000 square feet within a two-mile radius. Lifecore employs 406 full-time workers, all based in the United States. Its production sites maintain regulatory clearances and certifications from authorities in the United States, Europe, Japan, and Brazil.

Summary of the business section of Lifecore Biomedical, Inc. De's latest annual report, written by StockData.

Company profile

Company

Legal name
LIFECORE BIOMEDICAL, INC. DE
Founded
2007
Headquarters
Chaska, MN
Address
3515 Lyman Boulevard 55318
Phone
(952) 368-4300
Employees
382, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
May 25
Auditor
KPMG LLP, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
LFCR
Exchange
Nasdaq
IPO date
Feb 15, 1996
Shares outstanding
38M, Jul 29, 2026
Public float
$222.97M, Jun 30, 2025
Filer category
Accelerated filer<br>Smaller reporting company
SEC CIK
1005286
CUSIP
514766104
ISIN
US5147661046
LEI
549300EHBZ5OM9ND9O43
EIN
94-3025618

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Paul JosephsChief Executive Officer, Director592,915
Thomas D. SalusChief Legal & Administration246,333
Ryan David LakeChief Financial Officer336,691
Legion Partners, L.P. IIDirector2,968,409
Raymond T. WhiteDirector–
Legion Partners, L.P. IDirector4,507,236
Legion Partners Holdings, LLCDirector4,481,329
Legion Partners, LLCDirector2,940,340
Christopher S. KiperDirector2,998,409
Legion Partners Asset Management, LLCDirector4,461,823
Lovas Katrina HoudeDirector135,319
Nelson ObusDirector2,319,794
Joshua SchechterDirector135,080
Matthew E. KorenbergDirector69,967
Jason AryehDirector69,967
Paul Harold JohnsonDirector69,967
Humberto Calheiros AntunesDirector72,967

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Paul Josephs
$545.64K$2.42M$395.24K$68$118
FY2024
James GHall
$2.49M$1.69M$1.29M$47$93
FY2024
Paul Josephs
$10.25M$11.52M$1.29M$47$93
FY2023
Albert Bolles
$1.34M$640.59K$927.10K$66$79
FY2023
James GHall
$1.76M$1.40M$927.10K$66$79
FY2022
Albert Bolles
$956.81K$711.50K$687.61K$82$82

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“As of December 31, 2025, the Company had 382 full-time employees, of whom 177 were dedicated to manufacturing, 93 to quality and regulatory affairs, 78 to general operations, and 34 to sales, marketing and administrative activities.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 18, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 12, 2024Late filingNotification of late filing
Jun 7, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 14, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 30, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 19, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 8, 2024Late filingNotification of late filing
Mar 26, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 16, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 12, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 10, 2024Late filingNotification of late filing
Oct 18, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 10, 2023Late filingNotification of late filing
Aug 22, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 14, 2023Late filingNotification of late filing
Apr 14, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 10, 2023Late filingNotification of late filing
Feb 7, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 11, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 9, 2023Late filingNotification of late filing
Nov 7, 2022Name changeName changed from LANDEC CORP \CA\ to LIFECORE BIOMEDICAL, INC. \DE\
Sep 9, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 15, 2022Late filingNotification of late filing
Dec 17, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 7, 2019Late filingNotification of late filing
Apr 27, 2012Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 5, 2010Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 25, 2008Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 11, 2008Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 4, 2008Late filingNotification of late filing